Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data

Century Therapeutics presented new nonclinical data for CNTY-813, an investigational iPSC-derived islet replacement therapy targeting type 1 diabetes, at the 62nd Annual Meeting. The update supports continued development of the preclinical cell-therapy program, though the article provides no efficacy, safety, regulatory, or financial details.